Deep Vein Thrombosis (DVT)
Conditions
Keywords
Osteopathic treatment, Deep Vein Thrombosis, Proximal Leg DVT
Brief summary
Osteopathic treatment will provide: 1. A significant reduction of pain and swelling of the affected DVT leg 2. An increase in the quality of life (QOL) for individuals with DVT of the leg 3. Improved signs and symptoms of the post thrombotic syndrome of the affected DVT leg
Detailed description
Thousands of individuals are affected by deep vein thrombosis (DVT) every year. Medical treatment is aimed at preventing extension and recurrence of the blood clot (DVT) through the use of anticoagulation medication. Compression stockings may be added for reduction of pain and swelling, but this therapy remains controversial amongst physicians. To date, there is limited manual therapies available for individuals affected with DVT. Regular medical treatment, anticoagulation medication, along with osteopathic treatment may offer these individuals improved control of the symptoms associated with DVT. In the long term osteopathic treatment may provide an increase in the quality of life (QOL) and improve the signs and symptoms associated with the post-thrombotic syndrome (PTS), which can be burdensome for both the individual and the health care system. Offering an effective add on treatment could provide individuals and the medical system with an additional means of treatment for the symptoms of DVT and also for the prevention of development of PTS.
Interventions
The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
Sponsors
Nova Scotia Health Authority
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years of age and older * first episode of symptomatic objectively confirmed proximal leg DVT without pulmonary embolism * 1 month of appropriate anticoagulation treatment * therapeutic level of anticoagulation (ie: Warfarin, INR- 2.0-3.0)
Exclusion criteria
* \> 1 month + 7 days of anticoagulation * history of previously confirmed proximal or distal leg DVT * medically unstable individuals requiring hospitalization * history of peripheral vascular disease (PVD) * injury of affected leg (trauma within the last 6 months or leg currently casted) * history of previous stroke * uncontrolled hypertension * renal failure requiring hemodialysis or peritoneal dialysis * diagnosis of cancer in the last five years or currently receiving treatment for cancer * open heart or vascular surgery in the last year * any neurological condition (ie: MS, ALS, Parkinsons, etc) * currently pregnant * geographic inaccessibility * unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Swelling | 1 month pre and post testing and 2 months | Swelling will be measured using a tension-controlled tape measure at the initial study visit, one month after diagnosis of the subject's DVT and then again at 2 months after diagnosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Leg Pain | 1 month pre and post testing and 2 months | Leg Pain will be measured using the visual analogue scale (VAS), at the initial study visit(1 month after diagnosis of the DVT) pre and post assessment or assessment plus treatment. Pain will be evaluated again at the 2 month visit post answering questionnaires and lying supine for 10 minutes. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quality of LIfe (QOL) | 1 month and 2 months | Veines QOL/Sym Questionnaire will be completed by all participants at both study visits to determine if there have been any changes. |
| Assessment for Post Thrombotic Syndrome (PTS) | 1 month and 2 months | The Villalta scale will be used to assess subjects for signs and symptoms of the post-thrombotic syndrome at both study visits. |
Countries
Canada
Outcome results
None listed